In 2010, China's exports of traditional Chinese medicines achieved another breakthrough, reaching US$1.944 billion. There are four major characteristics of Chinese medicine exports.
The reporter learned from the China Chamber of Commerce for the Import and Export of Medicines and Health Products that in 2010, the import and export volume of Chinese medicines in China was 2.632 billion U.S. dollars, an increase of 22.74% year-on-year. Among them, the export value of 1.944 billion US dollars, an increase of 22.78%; import value of 688 million US dollars, an increase of 22.61%.
The growth rate of export of Chinese herbal medicines decoction pieces ranked second, and the price increase decreased. Affected by the increase in domestic prices of Chinese herbal medicines, the export of Chinese herbal medicines was boosted in 2010, and the average export price increased by 13.4% year-on-year. In 2010, the export volume of Chinese herbal medicines was 776 million U.S. dollars, an increase of 28.07% year-on-year, accounting for 39.89% of the total exports of Chinese herbal medicines. However, the volume of medicinal materials such as Fritillaria, Tianqi, Cordyceps sinensis, Coptis chinensis, and Atractylodes rose sharply, and the shrinkage of 30-40% was common.
The trade deficit of Chinese patent medicines has increased, and the increase in exports to the EU has fallen sharply. In 2010, China's proprietary Chinese medicines have been exported to 143 countries and regions, with an export value of 193 million U.S. dollars, an increase of 18.05% year-on-year; import value of 218 million U.S. dollars, an increase of 23.71% year-on-year. The trade deficit of Chinese patent medicines began in 2008 and increased in 2010. The countries with large increase in exports of Chinese patent medicines are Singapore, Malaysia and Hong Kong. China's Hong Kong, Japan and the United States are still the major export markets for proprietary Chinese medicines in China. The three countries account for about 57% of China's proprietary Chinese medicine exports. Hong Kong has become a transit point for Chinese patent medicines for global exports. The main sources of imports of Chinese patent medicines are Germany, Hong Kong, and Japan.
At the same time, Chinese medicine was affected by the European Union's "Registration of Traditional Plant Drugs Management Procedures" on April 30, 2011. In 2010, China's exports to the EU increased by only 15% year-on-year, far below the number of Chinese exports to the EU in previous years. The average annual growth rate of 25%.
The export of extracts is still the main force, accounting for 40%. In 2010, the export volume of China's extracts was US$815 million, a year-on-year increase of 17.62%, accounting for 41.92% of China's total merchandise merchandise exports. It maintained a growth trend and for the first time in many years occupied the top place in Chinese medicine export commodities; the import amount of extracts was US$130 million, up year-on-year. An increase of 7.16%, accounting for 18.95% of total imports of Chinese medicines. In 2010, the main export markets of China's plant extracts were still Japan and the United States, and EU countries with Germany, France, and the United Kingdom increased by more than 60%. The international demand for plant extracts remains strong.
The largest increase in exports of health products, imports still exceed exports. In 2010, China exported 161 million U.S. dollars worth of health products, an increase of 32.27% year-on-year; imports were 203 million U.S. dollars, an increase of 30.33% year-on-year. There are 98 exporting countries and regions, of which the countries with large increases in export value are the United States, Vietnam, and Indonesia. The United States and Japan are the major exporters of China, accounting for more than 60% of China’s exports of health products. However, the growth in exports to Japan has slowed down in recent years. Exports mainly include fish oil, inositol, seaweed and royal jelly products. Imports and exports of health products increased by the largest year-on-year in the trade of traditional Chinese medicines, but they still showed a large deficit, reaching US$42 million, a record high.
According to the analysis of the China Chamber of Commerce for Import and Export of Medicines and Health Products, in 2011, with the continuous increase in the demand for green products in the international market, traditional Chinese medicine products will continue to increase in export. The dominant products are mainly plant extracts, Chinese herbal medicines, and health products. commodity. While the international market continues to maintain strong demand for Chinese herbal medicine products, we must also see the implementation of the US CGMP ordinance, the implementation of electronic database verification and management of the import of Chinese herbal medicines, and the implementation of the EU's "Registration of Traditional Plant Drug Registration Procedures". It can be said that the examination paper placed before the Chinese medicine companies has become an important issue to be resolved in the Chinese medicine industry in 2011 and in the near future.
The reporter learned from the China Chamber of Commerce for the Import and Export of Medicines and Health Products that in 2010, the import and export volume of Chinese medicines in China was 2.632 billion U.S. dollars, an increase of 22.74% year-on-year. Among them, the export value of 1.944 billion US dollars, an increase of 22.78%; import value of 688 million US dollars, an increase of 22.61%.
The growth rate of export of Chinese herbal medicines decoction pieces ranked second, and the price increase decreased. Affected by the increase in domestic prices of Chinese herbal medicines, the export of Chinese herbal medicines was boosted in 2010, and the average export price increased by 13.4% year-on-year. In 2010, the export volume of Chinese herbal medicines was 776 million U.S. dollars, an increase of 28.07% year-on-year, accounting for 39.89% of the total exports of Chinese herbal medicines. However, the volume of medicinal materials such as Fritillaria, Tianqi, Cordyceps sinensis, Coptis chinensis, and Atractylodes rose sharply, and the shrinkage of 30-40% was common.
The trade deficit of Chinese patent medicines has increased, and the increase in exports to the EU has fallen sharply. In 2010, China's proprietary Chinese medicines have been exported to 143 countries and regions, with an export value of 193 million U.S. dollars, an increase of 18.05% year-on-year; import value of 218 million U.S. dollars, an increase of 23.71% year-on-year. The trade deficit of Chinese patent medicines began in 2008 and increased in 2010. The countries with large increase in exports of Chinese patent medicines are Singapore, Malaysia and Hong Kong. China's Hong Kong, Japan and the United States are still the major export markets for proprietary Chinese medicines in China. The three countries account for about 57% of China's proprietary Chinese medicine exports. Hong Kong has become a transit point for Chinese patent medicines for global exports. The main sources of imports of Chinese patent medicines are Germany, Hong Kong, and Japan.
At the same time, Chinese medicine was affected by the European Union's "Registration of Traditional Plant Drugs Management Procedures" on April 30, 2011. In 2010, China's exports to the EU increased by only 15% year-on-year, far below the number of Chinese exports to the EU in previous years. The average annual growth rate of 25%.
The export of extracts is still the main force, accounting for 40%. In 2010, the export volume of China's extracts was US$815 million, a year-on-year increase of 17.62%, accounting for 41.92% of China's total merchandise merchandise exports. It maintained a growth trend and for the first time in many years occupied the top place in Chinese medicine export commodities; the import amount of extracts was US$130 million, up year-on-year. An increase of 7.16%, accounting for 18.95% of total imports of Chinese medicines. In 2010, the main export markets of China's plant extracts were still Japan and the United States, and EU countries with Germany, France, and the United Kingdom increased by more than 60%. The international demand for plant extracts remains strong.
The largest increase in exports of health products, imports still exceed exports. In 2010, China exported 161 million U.S. dollars worth of health products, an increase of 32.27% year-on-year; imports were 203 million U.S. dollars, an increase of 30.33% year-on-year. There are 98 exporting countries and regions, of which the countries with large increases in export value are the United States, Vietnam, and Indonesia. The United States and Japan are the major exporters of China, accounting for more than 60% of China’s exports of health products. However, the growth in exports to Japan has slowed down in recent years. Exports mainly include fish oil, inositol, seaweed and royal jelly products. Imports and exports of health products increased by the largest year-on-year in the trade of traditional Chinese medicines, but they still showed a large deficit, reaching US$42 million, a record high.
According to the analysis of the China Chamber of Commerce for Import and Export of Medicines and Health Products, in 2011, with the continuous increase in the demand for green products in the international market, traditional Chinese medicine products will continue to increase in export. The dominant products are mainly plant extracts, Chinese herbal medicines, and health products. commodity. While the international market continues to maintain strong demand for Chinese herbal medicine products, we must also see the implementation of the US CGMP ordinance, the implementation of electronic database verification and management of the import of Chinese herbal medicines, and the implementation of the EU's "Registration of Traditional Plant Drug Registration Procedures". It can be said that the examination paper placed before the Chinese medicine companies has become an important issue to be resolved in the Chinese medicine industry in 2011 and in the near future.
Beverage Drops,Blueberry Extract Drink,Collagen Peptide Extract Drink,Vitamin D3 Cholecalciferol Drops
Weihai Baihe Biology Technological Co., Ltd. , https://www.biohighnutraceutical.com